A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression

  1. Arnaud Besson1,
  2. Mark Gurian-West1,
  3. Xueyan Chen1,
  4. Karen S. Kelly-Spratt2,
  5. Christopher J. Kemp2, and
  6. James M. Roberts1,3
  1. 1Howard Hughes Medical Institute, Division of Basic Sciences, 2Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA

Abstract

We have created two knock-in mouse models to study the mechanisms that regulate p27 in normal cells and cause misregulation of p27 in tumors: p27S10A, in which Ser10 is mutated to Ala; and p27CK–, in which point mutations abrogate the ability of p27 to bind cyclins and CDKs. These two mutant alleles identify steps in a pathway that controls the proteasomal degradation of p27 uniquely in quiescent cells: Dephosphorylation of p27 on Ser10 inhibits p27 nuclear export and promotes its assembly into cyclin–CDK complexes, which is, in turn, necessary for p27 turnover. We further show that Ras-dependent lung tumorigenesis is associated with increased phosphorylation on Ser10 and cytoplasmic mislocalization of p27. Indeed, we find that p27S10A is refractory to Ras-induced cytoplasmic translocation and that p27S10A mice are tumor resistant. Thus, phosphorylation of p27 on Ser10 is an important event in the regulation of the tumor suppressor function of p27.

Keywords

Footnotes

  • Supplemental material is available at http://www.genesdev.org.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1384406.

  • 3 Corresponding author.

    3 E-MAIL jroberts{at}fhcrc.org; FAX (206) 667-6877.

    • Accepted November 11, 2005.
    • Received October 14, 2005.
| Table of Contents

Life Science Alliance